AZD3427 for Heart Failure with Pulmonary Hypertension
(Re-PHIRE Trial)
Trial Summary
What is the purpose of this trial?
This study is intended to assess the ability of AZD3427 to reduce pulmonary vascular resistance (PVR) after 24 weeks of treatment in participants with heart failure (HF) and pulmonary hypertension (PH) Group 2
Do I have to stop taking my current medications for this trial?
The trial does not specify if you need to stop taking your current medications. However, participants must be on stable heart failure standard of care medication, including diuretics, to be eligible.
What data supports the idea that AZD3427 for Heart Failure with Pulmonary Hypertension is an effective drug?
The available research does not provide specific data on AZD3427 for Heart Failure with Pulmonary Hypertension. However, it mentions other treatments like pulmonary vasodilators, which are used for similar conditions. In patients with severe pulmonary hypertension due to lung disease, these treatments did not improve walking distance or functional class, but they did reduce a marker in the blood that indicates heart stress. This suggests that while there might be some benefits, the effectiveness of such treatments can vary depending on the specific type of lung disease. Further study is needed to determine if these treatments can slow disease progression.12345
What safety data is available for AZD3427 in heart failure with pulmonary hypertension?
The provided research does not contain any safety data for AZD3427 or its variants (AZD-3427, azd 3427, azd3427) in the context of heart failure with pulmonary hypertension. The studies focus on other treatments like selexipag, sodium nitrite, ambrisentan, and sitaxsentan for pulmonary hypertension.678910
Is the drug AZD3427 a promising treatment for heart failure with pulmonary hypertension?
Research Team
Eligibility Criteria
Adults over 18 with heart failure and pulmonary hypertension group 2, weighing at least 50 kg, on stable heart medications can join. They must have certain echocardiographic signs of PH and elevated artery pressure from a right heart catheterization. Excluded are those allergic to AZD3427 or similar drugs, who've had it before, with other types of PH, significant health issues, planned major heart procedures or severe lung disease.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- AZD3427 (Other)
Find a Clinic Near You
Who Is Running the Clinical Trial?
AstraZeneca
Lead Sponsor
Sir Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Dr. Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Parexel
Industry Sponsor
Peyton Howell
Parexel
Chief Executive Officer
Master of Healthcare Administration from The Ohio State University, Bachelor of Arts in Health Communications from the University of Illinois
Dr. Austin Smith
Parexel
Chief Medical Officer since 2023
MD from the Royal College of Surgeons in Ireland